NASDAQ:OCUL - Ocular Therapeutix Stock Price, News & Analysis

$4.48
+0.27 (+6.41 %)
(As of 08/16/2019 04:00 PM ET)
Today's Range
$4.24
Now: $4.48
$4.55
50-Day Range
$4.23
MA: $4.73
$5.36
52-Week Range
$2.35
Now: $4.48
$7.31
Volume374,800 shs
Average Volume609,953 shs
Market Capitalization$211.46 million
P/E RatioN/A
Dividend YieldN/A
Beta2.25
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OCUL
CUSIPN/A
Phone781-357-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.99 million
Book Value$0.17 per share

Profitability

Net Income$-59,980,000.00
Net Margins-3,450.84%

Miscellaneous

Employees167
Market Cap$211.46 million
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive OCUL News and Ratings via Email

Sign-up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.


Ocular Therapeutix (NASDAQ:OCUL) Frequently Asked Questions

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix Inc (NASDAQ:OCUL) announced its quarterly earnings data on Wednesday, August, 7th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by $0.15. The biopharmaceutical company earned $0.65 million during the quarter, compared to the consensus estimate of $1 million. Ocular Therapeutix had a negative net margin of 3,450.84% and a negative return on equity of 256.69%. View Ocular Therapeutix's Earnings History.

When is Ocular Therapeutix's next earnings date?

Ocular Therapeutix is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Ocular Therapeutix.

What price target have analysts set for OCUL?

6 brokerages have issued 12 month price targets for Ocular Therapeutix's stock. Their predictions range from $3.00 to $24.00. On average, they expect Ocular Therapeutix's share price to reach $9.6667 in the next year. This suggests a possible upside of 115.8% from the stock's current price. View Analyst Price Targets for Ocular Therapeutix.

What is the consensus analysts' recommendation for Ocular Therapeutix?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ocular Therapeutix.

Has Ocular Therapeutix been receiving favorable news coverage?

Press coverage about OCUL stock has been trending negative recently, according to InfoTrie. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Ocular Therapeutix earned a news impact score of -2.3 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Ocular Therapeutix.

Who are some of Ocular Therapeutix's key competitors?

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Celgene (CELG), Omeros (OMER), Cara Therapeutics (CARA), Egalet (EGLT), TG Therapeutics (TGTX), Melinta Therapeutics (MLNT) and Synergy Pharmaceuticals (SGYP).

Who are Ocular Therapeutix's key executives?

Ocular Therapeutix's management team includes the folowing people:
  • Mr. Antony Mattessich, Pres, CEO & Director (Age 52)
  • Mr. Donald Notman Jr., Chief Financial Officer
  • Dr. Michael H. Goldstein, Chief Medical Officer (Age 52)
  • Mr. Kevin F. Hanley, Sr. VP of Technical Operations (Age 57)
  • Dr. Peter K. Jarrett Ph.D., Chief Scientific Officer (Age 62)

Who are Ocular Therapeutix's major shareholders?

Ocular Therapeutix's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.23%), Man Group plc (4.57%), Vanguard Group Inc. (3.97%), Deltec Asset Management LLC (3.31%), Northern Trust Corp (0.89%) and JPMorgan Chase & Co. (0.68%). Company insiders that own Ocular Therapeutix stock include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag, Donald Notman, Jeffrey S Heier, Kevin F Hanley, Leslie J Williams, Michael H Goldstein and Richard L Md Lindstrom. View Institutional Ownership Trends for Ocular Therapeutix.

Which major investors are selling Ocular Therapeutix stock?

OCUL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Parametric Portfolio Associates LLC, GWM Advisors LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Ocular Therapeutix.

Which major investors are buying Ocular Therapeutix stock?

OCUL stock was bought by a variety of institutional investors in the last quarter, including Deltec Asset Management LLC, Man Group plc, JPMorgan Chase & Co., Vanguard Group Inc., BlackRock Inc., Sio Capital Management LLC, Royal Bank of Canada and Charles Schwab Investment Management Inc.. Company insiders that have bought Ocular Therapeutix stock in the last two years include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag, Donald Notman, Jeffrey S Heier, Kevin F Hanley, Leslie J Williams, Michael H Goldstein and Richard L Md Lindstrom. View Insider Buying and Selling for Ocular Therapeutix.

How do I buy shares of Ocular Therapeutix?

Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ocular Therapeutix's stock price today?

One share of OCUL stock can currently be purchased for approximately $4.48.

How big of a company is Ocular Therapeutix?

Ocular Therapeutix has a market capitalization of $211.46 million and generates $1.99 million in revenue each year. The biopharmaceutical company earns $-59,980,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Ocular Therapeutix employs 167 workers across the globe.View Additional Information About Ocular Therapeutix.

What is Ocular Therapeutix's official website?

The official website for Ocular Therapeutix is http://www.ocutx.com/.

How can I contact Ocular Therapeutix?

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at 781-357-4000 or via email at [email protected]


MarketBeat Community Rating for Ocular Therapeutix (NASDAQ OCUL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  304 (Vote Outperform)
Underperform Votes:  214 (Vote Underperform)
Total Votes:  518
MarketBeat's community ratings are surveys of what our community members think about Ocular Therapeutix and other stocks. Vote "Outperform" if you believe OCUL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCUL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel